Global Manufacturing Footprint Aurobindo Pharma operates approved manufacturing facilities recognized by USFDA, UKMHRA, WHO, MCC-SA, and ANVISA-Brazil, offering extensive global compliance and supply chain opportunities for partners seeking reliable and international-certified APIs and formulations.

Strategic Acquisitions With recent plans to acquire Zentiva Group for up to $5.5 billion and investments in American biologics facilities, Aurobindo demonstrates a strong growth trajectory and appetite for expanding its product portfolio and geographical reach, opening avenues for collaboration in high-value markets.

Robust R&D Capabilities Aurobindo’s focus on developing non-infringing processes, new drug delivery systems, and advanced formulations presents opportunities to partner on innovative product development and proprietary technologies tailored to regional and global markets.

Growth in Generics Market As one of India’s largest generic manufacturers with a revenue range of $250M to $500M, Aurobindo is well-positioned to expand its market share through strategic partnerships, licensing, and joint ventures, especially in high-demand therapeutic areas like antivirals, anti-diabetics, and antibiotics.

Market Expansion and Local Initiatives Recent event participation, local walk-in interviews, and regional presence in India indicate an active effort to strengthen local operations and facilitate sales within India, presenting opportunities for B2B engagement with regional distributors and healthcare providers.